#leo pharma

Collection of leo pharma news, found 8 news.

LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration ...

Article Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis

-Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 monthsAn analysis of ...

LEO Pharma Puts Patients at the Heart of Innovation

-      LEO Pharma announces a co-creation agreement with the National Psoriasis Foundation ...

Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

-     Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development ...

LEO Pharma and 4SC Discovery Announce Exclusive Research and License Agreement

-     LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into ...

International Study Highlights Need to Support Patients With Psoriasis

-     * LEO Pharma has conducted the first truly large scale international study informed by both ...

LEO Pharma Initiates Global Search for New Partners

-         LEO Pharma is now actively searching for new global or territorial ...

Four Phase 3 Efficacy and Safety Studies of Ingenol Mebutate

-        - NOT INTENDED FOR US MEDIA    - Ingenol Mebutate is an ...